Last reviewed · How we verify

Crowd Health Research, LTD — Portfolio Competitive Intelligence Brief

Crowd Health Research, LTD pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Epithelium-Off Riboflavin Epithelium-Off Riboflavin phase 3 Corneal cross-linking agent Corneal collagen (indirect via riboflavin photosensitization) Ophthalmology
Epithelium-On Riboflavin Epithelium-On Riboflavin phase 3 Corneal cross-linking agent Corneal collagen (photochemical cross-linking via riboflavin and UVA) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Cornea and Laser Eye Institute · 1 shared drug class
  2. Icahn School of Medicine at Mount Sinai · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Crowd Health Research, LTD:

Cite this brief

Drug Landscape (2026). Crowd Health Research, LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/crowd-health-research-ltd. Accessed 2026-05-16.

Related